Nontuberculous mycobacterial pulmonary disease (NTM-PD) is increasing in incidence globally and challenging to manage. The 2020 multisociety treatment guideline and the 2022 consensus recommendations provide comprehensive evidence-based guides to manage pulmonary diseases caused by the most common NTM. However, with >190 different NTM species that may require different multidrug regimens for treatment, the breadth and complexity of NTM-PD remain daunting for both patients and clinicians. In this narrative review, we aim to distill this broad, complex field into principles applicable to most NTM species and highlight important nuances, specifically elaborating on the presentation, diagnosis, principles of patient-centered care, principles of pathogen-directed therapy, and prospects of NTM-PD.

中文翻译：

---

非结核分枝杆菌肺疾病：患者、原则和展望


非结核分枝杆菌肺病 （NTM-PD） 的全球发病率正在增加，难以管理。2020 年多社会治疗指南和 2022 年共识建议为管理由最常见 NTM 引起的肺部疾病提供了全面的循证指南。然而，由于 >190 种不同的 NTM 物种可能需要不同的多药治疗方案，NTM-PD 的广度和复杂性对于患者和临床医生来说仍然令人生畏。在本叙述性综述中，我们旨在将这个广泛而复杂的领域提炼为适用于大多数 NTM 物种的原则，并强调重要的细微差别，特别是详细说明 NTM-PD 的表现、诊断、以患者为中心的护理原则、病原体定向治疗的原则和前景。